 |
Top 100 medical and healthcare startups in UK
Jan 14, 2025 | By Jason Kwon | 16 |
1
Funding: $30M
The future of AI-powered operating rooms. Using the latest in AI technologies to track surgery progress, tool usage and protocol adherence.
The future of AI-powered operating rooms. Using the latest in AI technologies to track surgery progress, tool usage and protocol adherence.
2
Funding: $100M
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.
3
Funding: $50M
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
4
Funding: $383.3M
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
5
Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
6
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
7
Funding: $180.4M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
8
Funding: $188M
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
9
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
10
Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
11
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
12
Funding: $1.2B
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
13
Funding: $1.1B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
14
Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
15
Funding: $540M
Myovant Sciences is to deliver innovative women's health (endometriosis treatment) and prostate cancer solutions by efficiently advancing new medicines to market.
Myovant Sciences is to deliver innovative women's health (endometriosis treatment) and prostate cancer solutions by efficiently advancing new medicines to market.
16
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
17
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
18
Funding: $351.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
19
Funding: $322.6M
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
20
Funding: $322.6M
Huma combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials
Huma combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials
